Lung adenocarcinoma (LUAD) is one of the most prevalent pathological kinds of lung cancer, which is a common form of cancer that has a high death rate. Over the past several years, growing studies have indicated that GPD1L was involved in the advancement of a number of different cancers. However, its clinical significance in LUAD has not been investigated. In this study, following an examination of the TGCA datasets, we found that GPD1L displayed a dysregulated state in a wide variety of cancers; this led us to believe that GPD1L is an essential regulator in the progression of malignancies. In addition, we found that the expression of GPD1L was much lower in LUAD tissues when compared with nontumor specimens. According to the findings of ROC tests, GPD1L was able to effectively identify LUAD specimens from nontumor samples with an AUC value of 0.828 (95% confidence interval: 0.793 to 0.863). On the basis of the clinical study, a low expression of GPD1L was clearly related with both the N stage and the clinical stage. Moreover, based on the findings of a Kaplan-Meier survival study, elevated GPD1L expression was a strong indicator of considerably improved overall survival (OS) and disease-specific survival (DSS). GPD1L expression and clinical stages were found to be independent prognostic indicators for overall survival and disease-free survival in LUAD patients, according to multivariate analyses. Based on multivariate analysis, the C-indexes and calibration plots of the nomogram demonstrated an effective prediction performance for LUAD patients. Besides, the expression of GPD1L was positively related to mast cells, eosinophils, Tcm, TFH, iDC, DC, and macrophages, while negatively associated with Th2 cells, NK CD56dim cells, Tgd, Treg, and neutrophils. Finally, qRT-PCR was able to demonstrate that GPD1L had a significant amount of expression in LUAD. Additionally, according to the results of functional tests, overexpression of GPD1L had a significant inhibiting effect on the proliferation of LUAD cells. In general, the results of our study suggested that GPD1L had the potential to serve as a diagnostic and prognostic marker for LUAD.

中文翻译：

---

鉴定 GPD1L 作为潜在的预后生物标志物并与肺腺癌的免疫浸润相关

肺腺癌 (LUAD) 是最常见的肺癌病理类型之一，是一种常见的癌症，死亡率很高。在过去几年中，越来越多的研究表明 GPD1L 参与了许多不同癌症的进展。然而，其在 LUAD 中的临床意义尚未得到研究。在这项研究中，在检查 TGCA 数据集后，我们发现 GPD1L 在多种癌症中表现出失调状态；这使我们相信 GPD1L 是恶性肿瘤进展中的重要调节因子。此外，我们发现与非肿瘤标本相比，LUAD 组织中 GPD1L 的表达要低得多。根据 ROC 测试的结果，GPD1L 能够从 AUC 值为 0 的非肿瘤样本中有效识别 LUAD 标本。828（95% 置信区间：0.793 至 0.863）。在临床研究的基础上，GPD1L的低表达与N分期和临床分期均明显相关。此外，根据 Kaplan-Meier 生存研究的结果，GPD1L 表达升高是显着改善总体生存 (OS) 和疾病特异性生存 (DSS) 的有力指标。根据多变量分析，发现 GPD1L 表达和临床分期是 LUAD 患者总生存期和无病生存期的独立预后指标。基于多变量分析，列线图的 C 指数和校准图证明了对 LUAD 患者的有效预测性能。此外，GPD1L的表达与肥大细胞、嗜酸性粒细胞、Tcm、TFH、iDC、DC和巨噬细胞呈正相关，同时与 Th2 细胞、NK CD56dim 细胞、Tgd、Treg 和中性粒细胞呈负相关。最后，qRT-PCR 能够证明 GPD1L 在 LUAD 中有大量表达。此外，根据功能测试的结果，GPD1L的过表达对LUAD细胞的增殖具有显着的抑制作用。总的来说，我们的研究结果表明 GPD1L 有可能作为 LUAD 的诊断和预后标志物。